Pentoxifylline Therapeutic Cheat Sheet
Pentoxifylline is a methyl-xanthine derivative traditionally used to treat symptoms of peripheral vascular disease and has emerged as a valuable therapeutic agent in dermatology for its anti-inflammatory and immunomodulatory properties. We continue our series, Therapeutic Cheat Sheet, with a closer look at pentoxifylline, which is FDA-approved for the treatment of intermittent claudication and is …
Pentoxifylline is a methyl-xanthine derivative traditionally used to treat symptoms of peripheral vascular disease and has emerged as a valuable therapeutic agent in dermatology for its anti-inflammatory and immunomodulatory properties. We continue our series, Therapeutic Cheat Sheet, with a closer look at pentoxifylline, which is FDA-approved for the treatment of intermittent claudication and is … 
Cemiplimab is a monoclonal antibody therapy that has emerged as a promising treatment option for certain types of advanced skin cancer. Specifically designed to target the programmed cell death protein 1 (PD-1) pathway, cemiplimab works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby unleashing the body's immune system to recognize and attack cancer cells. We con … 
Generalized pustular psoriasis (GPP) is a rare, autoinflammatory condition, with acute, severe flares of diffuse sterile pustules and systemic symptoms that can be life-threatening. Historically, cyclosporine, methotrexate, retinoids, and biologics modulating the interleukin-17 (IL-17), IL-23, and tumor necrosis factor α pathways have been used off-label for management.1 Aberrant IL-36 signaling … 
Bimekizumab (Bimzelx®) is a new injectable medication FDA approved for plaque psoriasis. It is the first and only FDA approved IL-17A and IL-17F inhibitor for this disease, but is also being used as an off-label option for other conditions including psoriatic arthritis and hidradenitis suppurativa. This Therapeutic Cheat Sheet will focus on the on and off label uses of bimekizumab.
Bimekizuma … 
Media attention about oral minoxidil has impacted access to the hair loss drug in the Washington, D.C. area, according to a study published in the January issue of the Journal of Drugs in Dermatology. Researchers found shortages of the drug in D.C.-area pharmacies more than a year after an article about the treatment appeared in The New York Times.
To find out more about oral minoxidil access, … 